Skip To Main Content
Mark C. Scholz on Muck Rack

Mark C. Scholz

As seen in: JAMA Oncology, Verywell Health, CURE Magazine, OncLive, Total Retail, European Urology, UroToday, Cerasis Blog, Red Carpet Crash
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Mark C.

Contact Mark C., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Risks of Taking Testosterone Treatments With Prostate Cancer

|
By Mark C. Scholz
| Verywell Health Verified
Testosterone replacement can be dangerous for men with prostate cancer if not managed carefully. It's generally safe for men who have low-risk prostate cancer and have completed treatment after an appropriate waiting period. Testosterone therapy may increase the risk of blood clots and heart problems, especially in older men. Testosterone replacement can be dangerous for people who have prostate cancer. When it is used, it has to be used with caution.
Open in Who Shared Issue with article?

How PSA Doubling Time Shows a Prostate Cancer Relapse

|
By Mark C. Scholz
| Verywell Health Verified
PSA doubling time is important for finding a relapse of prostate cancer. Treatment for a cancer relapse depends on PSADT and the cancer's original risk category If you or someone you're close to has prostate cancer, you'll hear a lot about the PSA blood test and the PSA doubling time (PSADT). PSA helps medical providers screen for and diagnose prostate cancer at an early stage. But there's more to the test than just that.
Open in Who Shared Issue with article?

Why Gleason 6 Prostate Cancer May Not Need Immediate Treatment

|
By Mark C. Scholz
| Verywell Health Verified
Gleason score 6 is the lowest grade of prostate cancer. This rating means that the prostate cancer is considered to be low- or very low-risk disease, or group 1. Most of these tumors are found during routine prostate cancer screenings. Gleason 6 prostate tumors grow slowly and may never cause a problem—or even need treatment. Still, they should be monitored. Screening for prostate cancer involves the prostate-specific antigen (PSA) test and a digital rectal exam.
Open in Who Shared Issue with article?
See all 13 licensed articles (15 Total)